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Abstract
Background: The Pennsylvania Cancer Alliance Bioinformatics Consortium (PCABC, http://www.pcabc.upmc.edu) is one 
of the ﬁ  rst major project-based initiatives stemming from the Pennsylvania Cancer Alliance that was funded for four years 
by the Department of Health of the Commonwealth of Pennsylvania. The objective of this was to initiate a prototype bio-
repository and bioinformatics infrastructure with a robust data warehouse by developing a statewide data model (1) for 
bioinformatics and a repository of serum and tissue samples; (2) a data model for biomarker data storage; and (3) a public 
access website for disseminating research results and bioinformatics tools. The members of the Consortium cooperate 
closely, exploring the opportunity for sharing clinical, genomic and other bioinformatics data on patient samples in oncol-
ogy, for the purpose of developing collaborative research programs across cancer research institutions in Pennsylvania. The 
Consortium’s intention was to establish a virtual repository of many clinical specimens residing in various centers across 
the state, in order to make them available for research. One of our primary goals was to facilitate the identiﬁ  cation of cancer-
speciﬁ  c biomarkers and encourage collaborative research efforts among the participating centers.
Methods: The PCABC has developed unique partnerships so that every region of the state can effectively contribute and 
participate. It includes over 80 individuals from 14 organizations, and plans to expand to partners outside the State. This 
has created a network of researchers, clinicians, bioinformaticians, cancer registrars, program directors, and executives from 
academic and community health systems, as well as external corporate partners - all working together to accomplish a com-
mon mission.
The various sub-committees have developed a common IRB protocol template, common data elements for standardizing 
data collections for three organ sites, intellectual property/tech transfer agreements, and material transfer agreements that 
have been approved by each of the member institutions. This was the foundational work that has led to the development of 
a centralized data warehouse that has met each of the institutions’ IRB/HIPAA standards. 
Results: Currently, this “virtual biorepository” has over 58,000 annotated samples from 11,467 cancer patients available 
for research purposes. The clinical annotation of tissue samples is either done manually over the internet or semi-
automated batch modes through mapping of local data elements with PCABC common data elements. The database cur-
rently holds information on 7188 cases (associated with 9278 specimens and 46,666 annotated blocks and blood samples) 
of prostate cancer, 2736 cases (associated with 3796 specimens and 9336 annotated blocks and blood samples) of breast 
cancer and 1543 cases (including 1334 specimens and 2671 annotated blocks and blood samples) of melanoma. These 
numbers continue to grow, and plans to integrate new tumor sites are in progress. Furthermore, the group has also developed 
a central web-based tool that allows investigators to share their translational (genomics/proteomics) experiment data on 
research evaluating potential biomarkers via a central location on the Consortium’s web site. 
Conclusions: The technological achievements and the statewide informatics infrastructure that have been established by 
the Consortium will enable robust and efﬁ  cient studies of biomarkers and their relevance to the clinical course of cancer. 256
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Studies resulting from the creation of the Consortium may 
allow for better classiﬁ  cation of cancer types, more accurate 
assessment of disease prognosis, a better ability to identify 
the most appropriate individuals for clinical trial participa-
tion, and better surrogate markers of disease progression 
and/or response to therapy. 
Background
Biomedical researchers, geneticists, pathologists 
and tissue engineers depend on cancer bioreposi-
tories for the development and validation of new 
diagnostic or prognostic cancer markers, the under-
standing of basic disease mechanisms, and the 
evaluation of proposed therapeutic regimens or the 
creation of new bio-engineered materials or phar-
maceuticals. Recent advances in translational 
research have resulted in a growing demand for 
speciﬁ  c, highly annotated human tumor tissues 
[1–3], and this demand has reinforced the impor-
tance of tissue banks as a major part of the neces-
sary infrastructure of any region seeking to become 
a force in medical biotechnology.
Although virtually all major academic cancer 
centers—in Pennsylvania and across the nation— 
have research tissue banks, it is still difﬁ  cult for 
most cancer researchers to ﬁ  nd sufﬁ  cient and well 
annotated tumor tissues that are necessary to begin 
and complete their work. This is because existing 
banks are beset by a number of major limitations: 
(1) the number of tissue specimens at a given site 
is limited, (2) sharing of information is constrained 
by conﬁ  dentiality and de-identiﬁ  cation issues, (3) 
the annotation process is complex and expensive, 
and (4) each tissue bank may deﬁ  ne and apply 
annotation differently. The result is that access to 
well documented tissue specimens, using normal-
ized descriptors, remains one of the most important 
limitations to cancer biomarker research[4].
In 1998, Pennsylvania’s leading cancer centers 
organized the Pennsylvania Cancer Alliance (PCA) 
and set as one of its ﬁ  rst goals the task of commu-
nicating to Commonwealth legislators and the 
Governor the need to allocate on a long-term basis 
a substantial portion of the funds from that year’s 
national Master Settlement Agreement with the 
tobacco industry[5] to research and prevention of 
diseases directly linked to tobacco use, including 
cancer. In 2001, the PCA’s efforts led to the 
Commonwealth legislators’ and the Governor’s 
decision to approve Act 77 [6], to allocate 19% of 
Pennsylvania’s tobacco settlement money for 
biomedical research initiatives that would be 
sponsored by the PA Department of Health’s 
Commonwealth Universal Research Enhancement 
(CURE) program [7]. The details of the allocated 
funds to this project are discussed below.
The Pennsylvania Cancer Alliance Bioinfor-
matics Consortium (PCABC, http://www.pcabc.
upmc.edu) is one of the ﬁ  rst major project-based 
initiatives stemming from the PCA, which was 
funded for three years by the Commonwealth. The 
objective of the PCABC was to initiate a prototype 
system for a Bioinformatics, Data Warehouse and 
Biorepository Project, by developing: (1) a state-
wide data model for bioinformatics; (2) a statewide 
repository of serum and tissue samples; (3) a data 
model for biomarker data storage; and (4) a public 
access website for disseminating research results 
and bioinformatics tools. The seven institutions 
comprising the Consortium have cooperated 
closely to (1) explore the opportunity for sharing 
clinical, genomic and other bioinformatics data on 
patient samples in oncology, (2) for the purposes 
of synergistically cooperating to share informatics 
and other expertise, and (3) of developing collab-
orative research programs across cancer research 
institutions in Pennsylvania. In many cases, clinical 
specimens reside in individual departments in each 
institution. These specimens are essentially 
unknown to the comprehensive research commu-
nity and thus underutilized. The Consortium’s 
vision was to provide a virtual repository of clinical 
samples located in various departments across the 
state, supported by a common and well standard-
ized informatics platform, in order to make them 
available for research. In addition, one of our 
primary goals was to facilitate the identiﬁ  cation of 
cancer-speciﬁ  c biomarkers and encourage collab-
orative research efforts among the participating 
centers. Details of this “virtual biorepository” for 
melanoma, breast and prostate cancers, tools for 
data mining, and the imaging storage and analysis 
software that make up the bioinformatics platform 
will be discussed.
Methods
Participating institutions
The PCABC was created to explore the opportunity 
for sharing clinical, genomic and other bioinfor-
matics data on patient samples in oncology, for the 
purpose of developing collaborative research 
programs across cancer research institutions in 257
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Pennsylvania. It is hoped that this activity will 
serve as a model for other regions, and be able to 
include multiple institutions in an enhanced 
research environment. The organization was 
initially comprised of University of Pittsburgh 
Cancer Institute, Fox Chase Cancer Center, 
Abramson Cancer Center of the University of 
Pennsylvania, Pennsylvania State Cancer Institute 
at Milton S. Hershey Medical Center, Fox Chase 
Cancer Center, Kimmel Cancer Center of Thomas 
Jefferson University, and The Wistar Institute. The 
Consortium has recently added new partners, that 
include the Geisinger Health System, Windber 
Research Institute, and Drexel University College 
of Medicine, and it is considering further expansion 
to include institutions from neighboring states. 
The Consortium has access to cases and research 
facilities from a variety of medical care settings 
that include major cancer centers, academic 
medical centers, research institutions, as well as 
rural community-based healthcare networks. This 
varied access allows the Consortium to encompass 
the wide diversity of patients with cancer that 
reﬂ  ects the demographics of the State of Pennsylvania 
and the surrounding areas and thereby expanding 
beyond the patient populations of the Cancer 
Centers’ component of the PCABC.
Organization of the consortium
The Consortium is governed by an Executive 
Group made of PCABC institute leaders, who 
oversee and guide Consortium’s development and 
ongoing activities. Figure 1 depicts the organiza-
tional chart of the Consortium. The skill set of each 
committee and types of roles that make up each 
committee are summarized in Table 1. The Execu-
tive Group has delegated tasks to several sub-
committees that included:
Disease/organ site sub-committees
Initially, a subset consisting of three target cancers: 
breast and prostate cancers and melanoma were 
selected to develop and implement a prototype 
system for evaluation of the complex elements 
necessary to enable the Consortium to succeed, as 
well as leveraging each of the member institutions’ 
well established research programs. The extension 
PCABC Organization Chart
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IP/Tech Transfer
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Data Managers 
Each site organized by  similar workflow/procedures:
Tissue  Bank(ers) – does tissue collection and Quality Assurance
Cancer Registrar – works with tissue bankers and data managers
to ensure outcomes data collection.   Acts as “honest broker”.
Oversees  HIPAA, Quality Improvement (QI) intiatives.
Data Manager – does  all  QA/QC   on entered data 
and Quality Control (QA/QC)
Figure 1. Organization Chart. The PCABC organization chart.258
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to additional cancers, as prioritized by the Execu-
tive Group, will follow the successful implementa-
tion of the prototype system by all members of the 
Consortium. In addition to storing the tissue 
samples with the needed clinical annotations, the 
Consortium aims to perform biomarker tests on 
the list of biomarkers compiled and agreed to by 
the Disease/Organ site sub-committee members. 
The Master List of purposed biomarkers is 
provided as supplemental ﬁ  le #1 with this manu-
script and is a compilation of biomarkers suggested 
by investigators from all member institutions.  The 
PCABC asked the research community to help the 
Consortium to determine which markers would be 
of interest strategically to compliment studies 
already underway or to add to banks of information 
already accumulated on a particular marker. For 
each biomarker submission, the PCABC asked the 
investigator to: 1) name the marker and primary 
cellular function or pathway involved in its impact 
on the neoplastic cell, 2) provide a short description 
of the background work done on this marker and 
why it would be important or at least worthwhile 
to pursue it as a therapeutic and/or diagnostic 
marker, and 3) designate the organ system site of 
most interest for exploring this marker explored, 
and the rationale behind its selection. The logic 
was to ask these well-published disease site experts 
and program leaders from each center to work with 
the Consortium in identifying biomarkers that have 
the most promise, with the intention of targeting 
those biomarkers ﬁ  rst and foremost. The Master 
List of purposed biomarkers is a “work in progress,” 
as each disease/organ sub-committee assembles to 
ration and prioritize the biomarkers of interest. This 
“Biomarker Master List” will be used as a guide 
for all research proposals requesting biospecimens 
from the Consortium. The Consortium does not 
expect that each organ site and biomarker will be 
studied by each institution. Instead, a scientiﬁ  c 
review group will be assembled as part of the 
committee structure of the PCABC, which will 
decide which biomarkers are performed on which 
tumor sites and by which partnering organizations. 
If certain biomarkers are able to be tested at 
multiple sites, the scientiﬁ  c review group along 
with the executive committee will decide which 
institution will be the preferred testing site and a 
second testing site for validation. Experimental 
results and biomarker data generated from the 
tissues utilized from the Consortium biorepository 
will be requested from the researchers at the 
member sites for inclusion within the database as 
described below.
Intellectual property (IP)/technology 
transfer sub-committee 
This group has the task of reviewing the issues 
surrounding how to deal with any intellectual 
property that develops as a result of the Consor-
tium’s efforts. This group is identifying how the 
Table 1. Skill set of committee members.
Summary of the required skill sets and roles that make up each of the committees of the PCABC organization.
Committee  Skill sets of committee members
Executive  Cancer Center Directors and principle investigators of grant
Scientiﬁ  c Review Group  Independent group of experts for each disease/organ category of interest
  and a liaison member from the working group.  Members include biostat 
  isticians, faculty, researchers, and physicians.
Intellectual Property (IP)/ 
Tech Transfer  General counsel, business development directors, technology transfer  
  directors, and faculty members
Disease Organ Site  Leading experts of organ/disease of interest, faculty and researchers,  
 physicians.
Institutional Review Broad (IRB)  Member of a IRB board, HIPAA regulatory specialist, tissue bank director,
  researchers, physicians, data managers
Common Data Elements (CDE)  Informaticians, molecular pathologists, microbiologists, oncology 
  informatics pathologists, genomics core directors, tissue bankers, cancer
  registrars, data managers, pathologists, researchers and others who
  bring a wealth of experience in collaborative data collection.
Working Group  Tissue bankers, cancer registrars, data managers, pathologists, 
  researchers, informaticians, post-doctoral fellows, database 
  administrators and project coordinators.259
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legislative language [6, 8] that dictates the grant 
award affects IP. The committee will begin to 
deﬁ  ne potential IP and has devised a framework 
inter-institutional agreement to deal with the 
technology transfer needs of the Consortium. 
Additionally, to protect each institution, the 
Consortium has carefully studied the biomarker 
list and their IP characteristics, to ensure that the 
IP protected markers will be performed by the 
institutions offering them and that there will be 
agreements between the institutions to protect 
both the patients’ privacy and conﬁ  dentiality 
when these biomarker assays are performed. This 
committee includes general counsel, business 
development directors, technology transfer 
directors, and faculty with experience in this 
important and complex area.
Institutional review board (IRB) 
sub-committee
This sub-committee had the initial task of: a) 
reviewing current practices within each center 
regarding sharing of banked tissue, b) comparing 
current patient informed consent samples, and 
beginning to develop a common standardized 
patient consent form and IRB protocol template, 
that all centers will use when collecting samples 
for analysis by the Consortium, and c) commu-
nicating with each center’s tissue banks to 
determine what tissue types and the number of 
samples that are sharable immediately. In 
addition, it is the Consortium’s intention that in 
subsequent years of the program, cross institu-
tional IRB will be generated to review specific 
uses of these tissues between institutions. For 
example, if a group at the University of 
Pittsburgh wanted to partner with the University 
of Pennsylvania in a melanoma project, a 
separate IRB that would address tissue specimens 
collected at both institutions and the exact 
nature of that research that would be performed 
will be the subject of a subsequent IRB. Hence, 
the initial proposed work will focus on allowing 
the PCABC partners to bank and share 
de-identified information through a central 
database in the goal of providing this informa-
tion for investigators across all member 
institutions that are part of this Consortium. The 
PCABC is fortunate to have on this committee 
an IRB chairman, a HIPAA regulatory specialist 
and a tissue bank director who can help direct 
the dialogue and provide thorough guidance to 
the Executive Group.
Common data elements (CDE) 
sub-committee
This important sub-committee was one of the ﬁ  rst 
to be organized, in order to decide what information 
on specimens and assays will be tracked. Standard-
ization and compatibility will be paramount to 
successful data sharing. To that end, the sub-
committee has broken down the task into nine 
modules: Patient demographics, family history, 
clinical history, genomic information, patient 
consent issues, pathology report, tissue sample 
descriptors, outcomes and biomarkers. The intent 
of this modularization is to enable generalizable 
CDEs to be commonly developed across tissues/
organs/cancers and to facilitate the swapping in/out 
of specialized modules as they are needed. 
However, because one of the initial goals was to 
enable the rapid implementation of a tissue and 
data repository for the Consortium in support of 
the biomarkers focus, the sub-committee focused 
the CDE development on the modules that allowed 
annotation of biospecimens. While utilizing and 
learning from the experiences of several others 
groups, the CDE sub-committee particularly took 
into consideration the experiences of the Coop-
erative Prostate Cancer Tissue Resource [CPCTR, 
see http://www.prostatetissues.org] [9, 10] as well 
as established open source standards including the 
Cancer Staging Manual[11] from the American 
Joint Committee on Cancer, the Data Standards for 
Cancer Registries from the North American Asso-
ciation of Central Cancer Registries [12], the 
College of American Pathologist’s Cancer Check-
list[13], and other biorepository speciﬁ  c CDEs that 
were available through the National Cancer Insti-
tutes Center for Bioinformatics [14, 15]. This 
committee is comprised of molecular pathologists, 
microbiologists, oncology informatics patholo-
gists, genomics core directors, and others who 
bring a wealth of experience in collaborative data 
collection.
Working group 
PCABC’s Working Group infrastructure consists 
of key personnel from each institution, which 
includes data managers, cancer registrars, tissue 
bankers, database administrators and project coor-
dinators who are responsible for day-to-day 260
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operations at individual sites as well as reporting 
progress to the central project coordinator.
Data Managers from each participating site 
act as the communicators and liaisons to the 
project coordination center. Responsibilities 
include managing the local site’s data entry and 
the site’s own de-identification link back to the 
patient identified data. A Data Manager is the 
point person for PCABC to communicate with 
regarding all clinical tissue and data collections 
and interactions with tissue bank directors and 
cancer registry managers from their respective 
institution. Data Managers will eventually be 
responsible for quality assurance standards 
within their center as they relate to data entered 
into the PCABC database.
Data Entry Personnel are any staff member who 
has access to the PCABC database and has the 
responsibility to review and/or enter data for their 
institution. These individuals review and dissemi-
nate data from various internal sources. Data entry 
personnel have the responsibility of entering the 
data accurately into the PCABC database. Often-
times, they work within the tissue bank or the tumor 
registry department of the participating center, as 
they have the training and experience necessary to 
provide accurate and timely entry of critical data. 
Each institution’s tissue bank(ers) is responsible for 
collection and quality assurance and quality control 
of the biospecimens shared with the Consortium. 
The Cancer Registrars work with tissue bankers and 
data managers, to ensure outcomes data collection, 
and act as “honest brokers” (see below) as well as 
assist in quality improvement initiatives with data 
annotation processes.
Human subjects protection—the 
honest broker concept
Each PCABC institute collects tissue and data 
locally according to the local and institutional 
guidelines and procedures. Tissue is stored locally 
but data management is done centrally. Each 
member organization has developed its own local 
protocols, including consent language describing 
its procedures to protect the conﬁ  dentiality and 
privacy of human subjects [16, 17] and has 
obtained local/institutional IRB approval for all 
PCABC activities.
The institutions that make up the Consortium 
ensure protection of patient identity through “The 
Honest Broker Concept”[18]. An “honest broker” 
or “tissue bank trustee” acts as a well-deﬁ  ned 
barrier between the clinical environment (in which 
fully identiﬁ  ed conﬁ  dential patient information is 
routinely exchanged as part of medical care) and 
general research community (in which all informa-
tion must be completely de-identified). In its 
simplest form, the honest broker is not part of either 
the clinical or research team and is the only person 
or organization that can link research identiﬁ  ers 
and clinical identiﬁ  ers. Although it differs between 
each PCABC organization, provisions are in place 
for the data managers, tumor registrars, tissue 
bankers, or local database administrators at the 
local PCABC sites to act as honest broker(s). Use 
of the honest broker system allows each organiza-
tion to control the de-identiﬁ  cation process and 
places responsibility and accountability for that 
process. Personal and clinical identiﬁ  ers (names, 
medical record numbers, etc.) are limited to the 
clinical space while research identiﬁ  ers (i.e. “subject 
12432” are never tied to the personal or clinical 
identiﬁ  es except in the honest broker’s code book. 
This concept differs from anonymization, which 
is a one way process of removing the linkage 
between personal identifiers with research 
identiﬁ  ers.
This concept is implemented by designating at 
least one tissue bank trustee from each institution 
to the central PCABC coordination site. For 
example, at one institution, a tumor registrar is 
designated as the tissue bank trustee since tumor 
registrars, by the nature of their job and by federal 
mandate already have access to clinical information 
on cancer patients and do not have access to the 
results of research data for tissue bank samples. The 
trustee is the only person who can link a patient with 
the tissue bank number that identiﬁ  es that patient. 
The trustee system ensures that new clinical 
outcome information can be added to a ﬁ  le identiﬁ  ed 
only by a code number, not a name. In rare but 
possible circumstances, when critical research data 
becomes available and it becomes medically neces-
sary to inform the patient or his survivors, the 
honest-broker system provides for an effective 
mechanism to ensure that the critical information 
reaches the interested party in a timely manner.
Central database design
The PCABC central database was modeled and 
expanded from the work of the Cooperative 
Prostate Cancer Tissue Resource (CPCTR) [9, 10]. 261
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The system is relational database designed as a 
virtual bio-repository that gathers information 
on banked tissues and patients in research trials 
—including clinical and molecular (gene and 
protein data)—from each of the Consortium 
member institutions. This data will be de-identiﬁ  ed 
at the local institutions and made available in a 
central data warehouse for visualization and 
query. 
The workﬂ  ow for entering data into the virtual 
bio-repository has been as follows:
1.  The local (physical) tissue bank identiﬁ  es cases 
appropriate for inclusion in the Consortium’s 
virtual bio-repository (warehouse). 
2. The local (physical) tissue bank pre-processes 
data on these cases. The most important com-
ponent of pre-processing is de-identiﬁ  cation. 
All de-identiﬁ  cation occurs at the local banks. 
No identiﬁ  able data is sent to the virtual bio-
repository (warehouse).
3. De-identiﬁ  ed data are entered into the ware-
house through a web site. The data entry web 
site uses radio buttons, combo boxes and other 
highly constrained data elements. 
4.  The local (physical) banks label each case with 
a de-identiﬁ  ed number. This number is used to 
link the information in the warehouse to the 
cases in the local banks. The linkage codes are 
stored locally, using appropriate electronic and 
physical safety measures. Only the local banks 
have access to these linkage codes. The database 
also keeps a system generated key that is tied 
to the de-identiﬁ  ed number that protects and 
secures the data links as an additional security 
measure.
5. The warehouse contains very minimal demo-
graphic data and complies with all HIPAA 
requirements. 
6.  Access to the data entry application is controlled 
by user name and password. Cases entered into 
the virtual bio-repository are scanned for logical 
errors (e.g. ﬁ  rst recurrence before diagnosis 
etc.).
The workﬂ  ow for querying the warehouse is as 
follows:
Initially, access is limited to members of the 
Consortium using a username and password 
system. The data manager at each facility is able 
to provide user names and passwords for approved 
researchers at that institution. The query tool 
accesses the central database through a highly 
constrained “click and point” interface. The data 
in the warehouse will eventually will allow queries 
on many of the approved data elements. However, 
the speciﬁ  city of the data returned will depend on 
the user’s proﬁ  le.
There are three user proﬁ  les as follows:
1. The Public Query tool is available to the general 
public and is accessible through the Consor-
tium’s web site [http://www.pcabc.upmc.edu]. 
The output display of a public query is the ac-
crued number of cases, specimens and blocks 
in the database that meet the criteria of the 
query and general statistics on a limited number 
of data elements. It is designed to allow inter-
ested investigators to see if there are enough 
tissue specimens available through the PCABC 
that meet their speciﬁ  c requirements.
2. Approved Investigator Query tool is password 
protected tool and is distributed to those research 
investigators who have approved research pro-
tocols within the PCABC or its member institu-
tions. It allows users to reﬁ  ne and compile case 
lists for their application and also to mine and 
modify the default data views on the cases they 
received biospecimens from the Consortium. It 
shows all the annotations on the data associated 
with each case through multiple pre-deﬁ  ned 
views of the data set. 
3. Data Manager Query tool is a password pro-
tected tool, available only for the internal 
PCABC members. It is meant for data managers 
to address QA issues regarding the data col-
lected from a speciﬁ  c institute and generating 
a tissue disbursement list. The main difference 
between this viewer and the Approved Investi-
gator Tool is that this tool allows the user to 
identify the institution from which the cases 
originated (i.e. UPCI, FCCC, PSU, etc.).
Application of use of material
Instructions on how to apply for specimens are 
available by contacting the PCABC central project 
coordinator. Should a researcher find tissue 
samples that may be useful in ongoing or proposed 
research from the PCABC query tool, the investi-
gator is requested to ﬁ  rst submit a letter of intent 
(LOI) indicating their proposed study and tissue 
requirements. The LOI is reviewed by the 
Executive Group or the Consortium’s Scientiﬁ  c 
Review Committee, consisting of an independent 262
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group of experts for each disease/organ category. 
Tissues are not released until after:
•  IRB approval of the study at the researcher’s 
institution—for patient safety of purposed 
research.
•  IRB approval of tissue collections at the tissue bank 
institution—for patient safety of biospecimens 
banked.
•  Approval of the Consortium’s Scientiﬁ  c Review 
Committee—to determine if the proposed 
research has validity and justiﬁ  es the use of 
potentially valuable tissue resources from the 
Consortium.
•  Approval of the local (physical) tissue bank - As 
“owner” and guardian of the tissue specimen 
(the local banks may have their own review 
committees or may wish to collaborate with the 
researcher).
Results
The PCABC has become a model of how to 
effectively partner across multiple and complex 
research institutions, to achieve the common goal 
of building a statewide or regional bioinformatics 
network. Currently, there are over 80 individuals 
who are members of this unique PCABC partner-
ship, which is continuously looking to expand to 
include new partners so that every region of the 
state as well as neighboring states can contribute 
and participate. This has created a network of 
researchers, clinicians, bioinformaticians, cancer 
registrars, program directors and external corporate 
partners - all working together to accomplish a 
common mission. 
The various sub-committees have developed a 
common IRB protocol template, common data 
elements for standardizing data collections for 
three organ sites, intellectual property/tech transfer 
agreements, and material transfer agreements that 
have been approved by each of the member insti-
tutions. This was the foundation work that has led 
to the development of a centralized data warehouse 
that has met each of the institutions’ IRB/HIPAA 
standards. The data warehouse has web-based 
interfaces for both data entry and query capabili-
ties. The data entry is either done manually over 
the internet or semi-automated batch ﬁ  les through 
mapping of local data elements with PCABC 
common data elements. A second, more important 
part of the warehouse is its ability to associate 
supplementary data sets, such as high throughput 
molecular data or other ﬁ  les, such as whole slide 
images of parafﬁ  n sections, by linking it with the 
originating specimen (and patient). Although these 
supplementary ﬁ  les are not fully integrated into 
the biospecimen warehouse, hyperlinks to separate 
databases or applications are provided for those 
cases that are known to have any additional ﬁ  les. 
The group has also developed a central web-based 
tool that allows investigators to share their trans-
lational (genomics/proteomics) experiment data 
on research evaluating potential biomarkers at a 
central location on the Consortium’s website 
[http://pcabc.upmc.edu/data/acctools]. In some 
cases, access to raw experimental data would be 
available to only internal PCABC members or 
would require communication and collaboration 
with the data originator. The many tools and capa-
bilities of the PCABC data warehouse are high-
lighted in Figure 2.
The design of the central database is developed 
to have normalized subset of standard clinical, 
pathological, outcomes and molecular and other 
biomarker descriptors, to enable Consortium 
members to utilize the warehouse to substantially 
complement their own local data repositories 
while making tissue specimens optimally avail-
able for use in translational and clinical cancer 
research.
Case accruals for the PCABC 
biospecimen data warehouse
Access to well qualiﬁ  ed tissue samples is funda-
mental to biomedical research. PCABC developed 
this site for the exchange of de-identiﬁ  ed informa-
tion on consented tissue samples available to 
Pennsylvanian and national researchers. This site 
is updated each morning [http://www.pcabc.upmc.
edu/main.cfm?dis=pqe]. Figure 3 shows the 
accrual rate of cases for each member institute by 
the cancer type.
As of January 2007, the “virtual biorepository” 
has over 60,000 individual annotated samples 
from 12,734 cancer patients available for research 
purposes. The Prostate Cancer Database currently 
holds information on 7327 cases (including 9424 
specimens and 46752 annotated blocks and blood 
samples). The Breast Cancer Database currently 
holds information on 3645 cases (including 4707 
specimens and 10325 annotated blocks and blood 
samples). The Melanoma Database currently 263
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holds information on 1762 cases (including 1591 
specimens and 2953 annotated blocks and blood 
samples). These numbers continue to grow, and 
plans to add more tumor sites are in progress. The 
accomplishments of the Consortium, since 
funding of this project in 2002, are summarized 
in Figure 4. A comparison of tissues banked with 
the cancer incidence data (race and sex) from the 
Pennsylvania Department of Health is described 
by Figures 5–8.
Information and resources available 
from the consortium
The PCABC website contains additional information 
about the Consortium, including a frequently asked 
questions (FAQ) section. Additionally, many of the 
key resource documents have been provided as 
supplemental ﬁ  les with this manuscript, such as:
•  The latest version of the Biomarker Master List 
(additional ﬁ  le #1)
•  The Intellectual Property /Technology Transfer 
Agreements (additional ﬁ  le #2)
•  Biomarker Disclosure Form (additional 
ﬁ  le #3)
•  Template IRB Protocol for PCABC project 
(additional ﬁ  le #4)
•  Template IRB Protocol for the Honest Broker 
system (additional ﬁ  le #5)
•  Universal Consent Template (additional 
ﬁ  le #6)
•  Material Transfer Agreement Template 
(additional ﬁ  le #7)
•  The freely available CDEs developed for breast, 
prostate, and melanoma by the Consortium can 
be downloaded from its public database link on 
the PCABC website. (additional ﬁ  les #8–10)
Alternatively, additional information can be 
obtained by contacting the project coordinator 
listed on the Consortium’s website [http://www.
pcabc.upmc.edu].
Discussion
Repository model
Each institution of the PCABC collects and stores 
specimens locally within their own tissue banks, 
while the data and information related to these 
specimens are maintained in a centrally located 
Upload Tools for Experimental Data sets
Data Storage Capability & Sharing
Mechanisms for translationalstudies and
other associated files.
Storage Capability
& Data Sharing
Mechanisms
for raw files of
experimental data
Experimental Data sets
Manual Data Entry Tools
using standardized CDEs
developed by PCABC
Associated with specimens
Data
Entry
Tools
Data sets for biospecimens and clinical
history checked for logical errors and proper
vocabulary prior to acceptance into database. 
Central
PCABC
Database
CDE Data
dictionary
Semi-automated Data Upload Tools
By mapping local legacy databases to
pre-formatted worksheets with
standardized CDEs
Bioinformatics Tools:
Gene Expression Analysis Tool
-Access and categorize previously
analyzed microarray data with
Gene Ontology, OMIM, GenBank,
Locus Link,Homologene,
PubMed, etc
Quality Assurance/Quality Control
(QA/QC) Protocols
for data and biospecimens that are
shared to the Consortium
Data Managers
Query Tool
Query Tools
based on user
login
HTML links to associated
experimental data sets:
-Microarrray data
-Whole slide images
-Tissue microarray data
Approved Investigator
Query Tool
Public Query Tool
Figure 2. PCABC Database Tools. The tools and applications developed by the Consortium and data warehouse’s capabilities are 
highlighted. 264
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bioinformatics and data management system that is 
accessible by the members of the network. Although 
the Consortium has been successful to date, the 
implementation of this decentralized collection and 
storage with a centralized data management model 
has resulted in several limitations that are discussed 
in the subsequent sections.
CDE issues
Creating the CDEs for the three initial disease types 
was modeled from the work of the Cooperative 
Prostate Cancer Tissue Resource. After their 
successful implementation of the prostate CDEs, 
the Consortium merely replicated the prostate 
CDEs and modeled the same format for the breast 
and melanoma CDEs within the data warehouse. 
However, as data entry began for the two later 
disease types, the difﬁ  culties of modeling them 
after the prostate CDEs surfaced. In particular, the 
prostate model allowed only one patient with one 
primarily disease to be entered along with associ-
ated tissue accessions pertaining to the primary 
disease; since once a prostate is removed, the 
patient does not have another primary prostate 
cancer. However, for other disease sites such as 
breast and melanoma, data on additional primary 
tumors of the same disease type cannot be accom-
modated within a single patient’s record using the 
system developed. The central data warehouse was 
a relational database, thus how data was entered 
and queried was limited by the constraint put by 
the design. The CDEs were arranged as:
•  Case or Patient Identiﬁ  cation number
 o Consent Information
 o Demographics and History
 o Progression and Outcomes
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 o Clinical and Pathological Staging Information
•  Treatment
•  Biomarker data (i.e. PSA)
•  Tissue Accession
 o Accession Level Pathology data
 o Block/Aliquot Level Pathology data
After initial implementation, several limitations 
were faced when data entry was done on the 
patients who had multiple primaries from the same 
disease/organ site. For example, the current design 
only allowed the input of staging information once 
per patient record. To bypass this issue, separate 
records with the patient identiﬁ  cation number 
assigned as 12345-A, 12345-B, etc. were entered 
into the database for cases that had multiple 
primary diseases from the same organ site. 
However, this solution presents its own set of 
issues. For instance, when a patient’s vital status 
is presented as “dead”, the question of which of 
the two primaries was the cause of death is raised. 
Another issue is when updating this key informa-
tion or other follow up data, multiple ﬁ  les of the 
same patient would have to be updated for a single 
piece of information. Furthermore, the ability to 
search for cases with multiple primaries would not 
be integrated, thus lessening the true value of such 
cases for research studies.
IRB issues
Members of the IRB sub-committee addressed any 
privacy issues that might be of concern at indi-
vidual IRB committees. Developing a standard 
IRB protocol that would be common at each insti-
tution for the entire project was a key step for the 
Consortium, especially as it related to data sharing 
in the PCABC biorepository data warehouse. 
Several institutions encountered delays in getting 
its IRB to approve the goals of the project. The 
primary concerns of the IRB were 1) how and why 
were data de-identiﬁ  ed instead of annonymized? 
2) Who has ownership of the tissue? 3) Who was 
allowed the usage of tissues/data from the Consor-
tium? And 4) how was it determined who was given 
tissues/data from the Consortium? 
In order to resolve these concerns, the project 
coordinators conducted on-site meetings and 
conference calls with individual site IRBs, to 
address their concerns as well as educate and train 
members of the Consortium on the role of cancer 
registries, training of HIPAA guidelines, and imple-
Summary of the accomplishments of the PCABC
Major milestones since initial funding of the project in 2002
Aug-98
Aug-02
Jun-03 Applied for and received
$4.08M in federal funding
“Cancer Biomedical Informatics Grid” caBIG
[http://cabig.nci.nih.gov/]
leveraged from the established
synergy of the PCABC collaboration.
Dec-04
Jul-03
Jul-05
Sep-05
Jan-06 Jan-05 Jan-04
Over 375 whole slide images
on prostate cases linked to
originating specimen at patient level.
Mar-05
May-04
Oct-05
Establishment of partnership with
NCI Cooperative Prostate Cancer
Tissue Resource (6100 cases
and in 5th year of funding)
[http://www.prostatetissues org]
Feb-04
Established procedures for
intellectual property/Technology transfer,
IRB protocols, universal consent,
patient privacy using Honest Brokers,
and QA/QC of data and biospecimens.
Mar-03
Establishment of partnership with
NCI Cooperative Breast Cancer
Tissue Resource (9000 cases
and in its 14th year of funding)
[http://cbctr.nci.nih.gov]
Nov-05
Feb-06
Director’s Challenge dataset
(62 prostate cases) linked to
originating specimen at patient level.
CPCTR TMA #2
(250 prostate cases) linked to
originating specimen at patient level.
CPCTR TMA #1
(299 prostate cases) linked to
originating specimen at patient level.
Jan-03
Jan-03
Apr-03
Developed new CDEs for
breast and melanoma
based on CPCTR’s
prostate model.
Agreed to a data warehouse model
for storing biospecimen, clinical,
biomarker data with capablities to
re-annotate experimental datasets.
Jun-02
The PCABC received an initial
$5.6 million grant from the
Pennsylvania Department of Health
as part of a peer-reviewed competition
for Non-formula Tobacco Settlement funds.
Biomarker/Supplementary data annotation:
9 datasets of experiment results from
genomics/proteomics projects uploaded.
Applied for and received
$500,000 pre-pilot project
through Pittsburgh Life Science Greenhouse
New 7th and 8th partner:
Geisinger Health System and Windber Research Institute.
The Pennsylvania Cancer Alliance
(PCA) is organized.
Agreed to a solid data management
structure with clearly delineated
responsibilities and decision making.
Developed and now use a common
data entry tool over the web
(secure, Health Insurance Portability
and Accountability Act [HIPAA] compliant).
Developed and now use a common
data query tool based on the
agreed common data elements.
Figure 4. PCABC Timeline. Summary of the accomplishments of the PCABC since initial funding of the project in 2002.266
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mentation of the Honest Broker system [18]. It was 
explained to the IRBs that it was critical to have 
cases that were entered into the Consortium to be 
de-identiﬁ  ed so that follow-up information can be 
added as well have the ability to re-annotate those 
cases with experimental data sets when tissues 
were used for research studies. It was also noted 
that the ownership of the tissues is always retained 
with the “tissue bank(s)” of each institution. Full 
governance for all tissue and its associated data 
was in place within the Consortium and distributed 
to only those 0requests with all the appropriate 
approvals mentioned above were obtained. 
Furthermore, the creation of the multiple query 
views based on the user’s proﬁ  le was directly 
related to the concerns of the IRB. An issue was 
raised that although there was a governance place 
on how tissue was requested, how was access to 
the data warehouse limited to potential users. 
Besides the privacy issues, the concern was that 
having detail information on individual cases 
would introduce case selection bias for potential 
research studies. 
Data annotation methods—manual 
vs. automated
Originally, the partners envisioned primarily a manual 
annotation methods by using web-based data entry 
interfaces, but we quickly discovered this was too 
time consuming as many centers had “legacy” data-
bases that required researching and compiling 
archived data. Developing standardized parsing and 
semi-automated data entry methods with those insti-
tutions by adapting data mapping methods to created 
ﬂ  at ﬁ  les that allowed alternative methods of batch 
uploads to the central data warehouse. However, the 
ability to implement these semi-automated techniques 
varied at each institution depended on the IT (infor-
mation technology) support staff availability. Some 
institutions had large sophisticated legacy databases 
as well as access to other hospital base systems, such 
Figure 5. Percentage of Prostate Tissues Banked compared to Incidence Reported in Pennsylvania.
Comparison of Prostate Tissues Banked in PCABC to Incidence reported to State DOH by Race.
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as tumor registry systems; those programmers and 
database administrators were able to map the required 
PCABC data elements with their internal data 
sources. Some institutions had minimal informatics 
infrastructure to support their homegrown databases 
(i.e. Access), with limited or no domain knowledge 
and expertise. These scenarios required the central 
PCABC database administrators to educate those 
institutions regarding the required format of the stan-
dardized export ﬁ  les. Of note, those institutions where 
no previous tissue bank existed, the data entry tool 
allowed for quick deployment of informatics tools 
that not only helped with case accruals for the Consor-
tium, but also for alternative ways of managing their 
local tissue bank.
Issues of semantics
The legacy databases lack the ability to exchange 
information and semantic interoperability, which 
is the ability to understand and use the information 
once it is received by other systems. Another 
problems is that the panoply of ways that similar 
or identical concepts or data are described by 
different users even within the same institution. For 
example, a data element called “grade of tumor” 
can be collected using various formats (e.g. some 
collect “grade-1, grade-2, and grade-3” vs. others 
who collect “low grade, intermediate grade, and 
high grade”). Such inconsistency in data descrip-
tors makes it nearly impossible to aggregate and 
manage even modest-sized data sets in order to be 
able to ask basic queries. Moreover, these systems 
are not uniform and ﬂ  exible as well as incapable 
of performing easy transfer of information and 
unambiguous interpretation of the information 
once it arrives into a central database. 
However, our current database is based on such 
a bioinformatics model that aids in developing and 
conveying the semantic interoperability of the data 
system by describing the common data elements 
in the form of metadata or data descriptor (about 
the content, quality, condition, and other 
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characteristics of the data) using controlled vocab-
ulary and ontology, in order to make the data 
understandable and sharable for end-users and 
ﬂ  exible for the system. Each common data element 
is associated with an object or concept, attribute, 
and valid value(s). For example, “patient age at 
diagnosis” is the CDE that is made up of “patient” 
(object), “age at diagnosis” (property) and the 
representation (value domain) in “years”. Thus, in 
order to share quality data into the PCABC central 
database, the data collectors at each site need to 
understand what exactly needs to be collected, as 
has been agreed by the members of CDE sub-
committee. Speciﬁ  cally for each of the approved 
CDEs, the data collectors need to know: 1) the 
fundamental deﬁ  nition of the data element (i.e. 
date of diagnosis), 2) how that data element will 
be collected (e.g. 11/2003 vs. Nov. 2003 vs. 11/03, 
etc), 3) what are the consensus acceptable values 
or codes are for the data element (e.g. precise date 
of birth, not calculated from clinical records where 
the “patient appears to be a well developed 75 year 
old”), and 4) what the acceptable data format is for 
inclusion into the central database (e.g. dates as 
integers not character strings). Although the 
concept of formalized metadata is fairly straight 
forward, it has been rarely incorporated by clinical 
and research groups building databases[19].
The CDEs developed by the Consortium are 
ISO/IEC 11179 compliant (International Standards 
Organization / the International Electro technical 
Commission) [19,20] that means it defines a 
number of ﬁ  elds and relationship for metadata 
registries including detailed metamodel for 
defining and registering items, of which the 
primary component is a data element. The PCABC 
uses CDE standards and metadata that are deﬁ  ned 
by the consortium members of participating insti-
tutions. Furthermore, the Consortium members, 
through their work in the caBIG initiative[21], are 
working to enhance the database as a similar 
object-relational model as PCABC as well as some 
Figure 7. Percentage of Melanoma Tissues Banked compared to Incidence Reported in Pennsylvania.
Comparison of Breast Melanoma Banked in PCABC to Incidence reported to State DOH by Race.
Comparasion of Melanoma Tissues Banked in PCABC 
to Incidence reported to PA State DOH by Race*
86.3%
0.5%
13.2%
93.0%
0.3%
6.6%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
White
Race
P
e
r
c
e
n
t
a
g
e
PCABC
STATE (PA) 
*Based on PCABC tissue accrual rates from all member institutions on June 2006. The PA State incidence data based on total number of cancer 
cases by Race and Sex-Pennsylvania Residents, 1999-2003 ("PA Caner Incidence and Mortality Report 2003" by the PA Department of Health,  
published July 2006).
Black Other269
Multi-Institute Approach to Translational Cancer Research
Cancer Informatics 2007:3 
of the CDEs by using pre-defined controlled 
vocabulary systems like those in NCI Thesaurus[22] 
(NCI Thesaurus is a knowledgebase that contains 
the working vocabulary used in data systems 
covering clinical, translational and basic research 
as well as administrative terminology) with seman-
tically integrated and globally accepted valid 
values for each data elements. PCABC has the 
Oracle platform with internal object model, 
whereas caBIG creates its own object model and 
forms the data standard repository taking package, 
class, attribute, and data type into consideration on 
a Java template. This differs from the current 
PCABC practices, in that, caBIG attempts to use 
these “globally” accepted CDE standards and 
metadata descriptors recommended by multiple 
voluntary organizations and groups from the 
research community that will allow all NCI-spon-
sored research to share data more easily. By taking 
this new approach, greater ﬂ  exibility will be given 
to individual institutions with the current limitations 
placed in data collection methods and work ﬂ  ow. 
As another example, for the CDE “Patient race”, 
the object is “patient”; property is “race” and the 
valid value or representation of the metadata 
(“Caucasian”, “African American”, “Asian”, etc). 
If legacy databases from one institution uses 
“African American” and another institute uses 
“Black” as a valid value for the “race” ﬁ  eld and 
both their CDEs and metadata are properly mapped 
to the central database, then when researchers 
query for “African American” cases in the Consor-
tium’s user interface, the result would display the 
total cases (“African American” plus “black”) 
available from both institutions, because both 
terminologies are semantically integrated with the 
accepted system. Hence, the overall advantage of 
a distributed or federated model like caBIG over 
a centralized model like PCABC include the shared 
responsibilities of individual institutions for 
services and implementation of the required stan-
dards and vocabulary that would foster data sharing 
*Based on PCABC tissue accrual rates from all member institutions on June 2006. The PA State incidence data based on total number of cancer 
cases by Race and Sex -Pennsylvania Residents, 1999-2003 ("PA Caner Incidence and Mortality Report 2003" by the PA Department of Health, 
published July 2006).
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effortlessly. Furthermore, the centralized PCABC 
architecture has a data sharing model inbuilt that 
controls the various participating institutions. The 
implementation of federated systems do not have 
inbuilt data sharing models, but rather services that 
run as external grid services, which connects with 
local databases to establish such data sharing 
mechanisms. The importance of semantic integra-
tion cannot be over emphasized.
Data integration of high throughput 
datasets
Although more work needs to be done, the Consor-
tium’s current database design has limited integra-
tion capabilities of supplementary data sets, such as 
high throughput molecular data or other ﬁ  les, such 
as whole slide images of parafﬁ  n sections, by linking 
it with the originating specimen (and patient) [23–
25]. Unlike classical tissue annotation and clinical 
data, high throughput techniques generate a large 
amount of well formatted and semantically inte-
grated data, typically for a relatively small number 
of tissue specimens. These data require signiﬁ  cant 
computation analysis, usually using several different 
approaches. The development of new tools for 
analysis of molecular research data is presently an 
area of intense research and focus of other major 
initiatives in the vocabulary workspace domain of 
caBIG infrastructure [21]. Data standards for high 
throughput data are only now being developed and 
there is no single standard that meets the needs of 
all researchers. Development of a metadata reposi-
tory may resolve this issue. 
Tissue/data ownership issues
Numerous annotated tissue repositories already 
exist at most large academic institutions and 
cancer centers. In order to make them available 
to a wider research community, much work needs 
to be performed to educate those tissue banks 
about the beneﬁ  ts of sharing their resources in 
collaborative projects such as the PCABC. One 
success of the PCABC was to take an inventory 
of existing projects that possibly could partner 
with the Consortium. This led to the partnership 
with the CPCTR, with its data being shared in 
the PCABC data warehouse. In addition, there 
are multiple collections of similar disease/organ 
types within a single organization that individuals 
are either not aware of or cannot access. 
Furthermore, many tissue bank-focused projects 
do not consider the vast resources of parafﬁ  n 
archives that are available for use, that is housed 
in many academic pathology departments [26]. 
In order to resolve these issues, project leaders 
from many developing and ongoing collaborative 
projects [21, 27–36] need to provide incentives 
to all parties, especially to all those tissue banks 
that already exist, to collaborate and to build upon 
what they have learned without “re-inventing” 
much of the infrastructure.
Funding
The key feature to improve the management and 
prevention of cancer is the novel ideas that come 
from research, and the pace of research is 
directly related to the availability of advanced 
technology and top talent, together with the 
infrastructure needed to financially support 
them. A successful research effort therefore 
requires a steady, reliable commitment of 
support, and the tobacco settlement offers Penn-
sylvania an opportunity to make that crucial 
long-term commitment and to measure the 
results of its investment in lives saved. 
On November 16, 1998, the Commonwealth of 
Pennsylvania and 45 other states and territories 
entered into an historic settlement with the tobacco 
industry [5]. Under the terms of the Master Settle-
ment Agreement, the tobacco industry will pay the 
states $206 billion over 25 years. Pennsylvania’s 
share of that settlement is valued at more than $11.2 
billion [37]. This settlement presents Pennsylvania 
with an opportunity to invest in research that will 
reap beneﬁ  ts for all its citizens for generations. The 
PCABC was awarded $5.5 million for a three year 
project as one of the ﬁ  rst unique collaborative 
projects seeking to promote cancer research 
throughout the state by utilizing the funds of the 
tobacco settlement [38]. The Commonwealth’s 
goal of funding such a project was to create a 
bioinformatics infrastructure for a biorepository of 
body ﬂ  uids such as blood, serum, urine, etc. and 
tissue samples which, in turn, put the Consortium 
in a better position as a group to compete for addi-
tional funding to advance cancer and bioinfor-
matics research. In addition, the Commonwealth 
hoped to facilitate collaborations not only among 
the researchers who are members of the Consor-
tium, but also with outside collaborative partners 
such as pharmaceutical and biotechnology compa-
nies, the Life Sciences Greenhouses [39], and 271
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researchers and institutions outside of the 
consortium to energize economic growth throughout 
the state.
According to a study produced by the Tripp 
Umbach ﬁ  rm [40], since its start in 2001, the CURE 
program has provided $298 million for medical 
research in Pennsylvania using the tobacco money. 
That has resulted in a $544 million boost to the 
state’s economy—a nearly two-to-one return on 
investment. More than 4,000 high paying jobs were 
created or sustained in every sector of the economy 
through CURE funding, and $32 million in new 
tax revenue for the state was generated. In addition, 
many members of the PCA successfully leveraged 
the CURE funds to secure $138 million in new 
federal medical-research funding as well as $500 
thousand from the Pittsburgh Life Sciences Green-
house [39] to add two new members to the Consor-
tium. Figure 4 shows the additional funds generated 
by the members of the PCABC.
In spite of the successes mentioned above, it 
cannot be emphasized enough that one of the 
fundamental issues related to building and 
managing a biorepository is the large ﬁ  nancial 
commitment needed by various stakeholders 
involved. In addition to the millions of dollars spent 
by other international biorepository initiatives 
[27–34], a recent report by the NCI Advisory 
Bodies estimated over $50 million is spent annually 
by the NCI on biorepository-related activities [41, 
42]. Furthermore, a report by RAND corporation 
[2] states that accurate determination of the actual 
costs of collecting, processing, storing, and distrib-
uting tissue samples as well its supporting infor-
matics infrastructure and operating costs need to 
be determined as a “best practice” for cost recovery 
to ﬁ  nancially sustain future biorepositories. This 
highlights the importance of standardizing and 
sharing tools by all groups so that unnecessary 
efforts are not duplicated, as well as, similar groups 
can build upon the lessons learned by others. As 
the Consortium prepares to open its biorepository 
for requests by interested researchers, it is still 
unclear whether it will be able to become self-
funding through fees generated by specimen 
requests. 
Utilization and marketing 
of the PCABC biorepository
As reveal above, a large ﬁ  nancial commitment is 
needed for a project like the PCABC to completely 
be operational and self-sufﬁ  cient. Leveraging the work 
done by other collaborative groups [43, 44] that had 
two member institutions of the PCABC was a key 
factor for much of the success the Consortium 
consummated with its limited funding. When 
compared, each member of the NCI collaborative 
groups received on average over $1 million/year 
[45–47] as opposed to each of the initial seven PCABC 
member institutions receiving approximately $262K/
year (PCABC total budget = $5.5mil/3years). The 
members of the PCA do acknowledge that much work 
still needs to be addressed in terms of marketing this 
resource developed for the research community. Much 
of the utilization of the biospecimens to date has been 
limited to a handful of pilot studies between the 
member institutions and numerous requests through 
partnerships with collaborative tissue groups from the 
NCI [43, 44]. Furthermore, the Consortium set its 
priority on several issues that needed to be addressed 
prior to the onset of utilization of the tissue resources. 
These issues included (1) intellectual property issues 
between the users and providers of the resources, (2) 
IRB issues related to conﬁ  dential and privacy sharing 
of tissues and data across multiple institutions, and (3) 
infrastructure issues dealing with a common bioinfor-
matics platform. As described by other repositories 
[3], marketing a biospecimen resource like the 
PCABC to the broader research community will also 
be a key factor in measuring its success for utilization 
of the biospecimens. However, with substantial new 
federal funding from the National Cancer Institute’s 
cancer Biomedical Informatics Grid (caBIG, see 
http://cabig.nci.nih.gov) initiatives [21], the members 
of the PCABC are committed to sustaining and 
continue to build the infrastructure developed by the 
Consortium, and are conﬁ  dent that its investment will 
provide an invaluable resource for large scale cancer 
biomarker research, that will lead to the demonstration 
of multiple new biomarkers as clinically important 
guides to tumor classiﬁ  cation, prognosis, response to 
therapy, and/or clinical course of disease.
Conclusion
The technological achievements and the state-
wide informatics infrastructure that have been 
established by the Consortium will enable robust 
and efficient studies of biomarkers and their 
relevance to the natural history and clinical 
course of cancer. Studies resulting from the 
creation of the Consortium may allow for better 
classification of cancer types, more accurate 272
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assessment of disease prognosis, a better ability 
to identify the most appropriate individuals for 
clinical trial participation, and better surrogate 
markers of disease progression and/or response 
to therapy. Of significance, the bioinformatics 
infrastructure, data warehouse, and bioreposi-
tory created through Consortium activities will 
serve as a model as well as catalyst, and would 
be made available for use by researchers and 
institutions and other collaborative groups that 
are presently not part of this research effort. 
In summary, the Pennsylvania Cancer Alli-
ances Bio-informatics, Data warehouse and 
Bio-repository project has created a central 
resource through which researchers can find 
highly annotated tissue samples. The resource 
will have no access at any time to patient iden-
tified data and tissue will not be made available 
to researchers without the approval by IRB and 
Scientific Review Committee. Furthermore, we 
believe that the cancer centers of Pennsylvania 
have the skills and experience necessary to 
develop, build and implement a statewide 
network of highly annotated tissue specimens 
with relevant demographic, clinical, molecular, 
and outcome data for biomedical research. 
Based on the successful implementation of this 
system, the Consortium hopes other groups 
initiating similar projects will build upon the 
lessons learned from the PCABC, for some of 
the most important problems in biomedical as 
well as clinical informatics, including medical 
record de-identification, data mining tools and 
complex data warehousing of biology data. By 
integrating multimodal (pathological, clinical 
and molecular) data in the annotated tissue 
repository, creating query, visualizing tech-
niques for these diverse data types and by 
making this information available statewide, we 
can help to provide much better selected and 
characterized tissues for research. In the process, 
we hope to foster new understanding of disease 
evolution and progression that would eventually 
help make Pennsylvania a leader in cancer 
research and biomedical technology. 
Acknowledgements
This work was supported in part by Pennsyl-
vania Department of Health grant: PA DOH ME 
01–740.
We acknowledge all the following contributors 
to the development of the PCABC:
University of Pittsburgh Cancer Institute 
Nancy Whelan, Lois Mathews, Sharon Winters, 
Susan Urda, Heidi Gianella, Michelle Bisceglia, 
Rajnish Gupta, Harpreet Singh, Songhui Li, Yimin 
Nie, Vicky Chu, Sambit Mohanty, Dorothy Mann, 
Linda Mignogna, Federico Monzon-Bordonaba, 
Alice Katsur, John Kirkwood, Adam Brufsky, 
Theresa Colecchia, and Carolyn Green.
Abramson Cancer Center of the 
University of Pennsylvania
John Glick, Jesse Tigges, David Fenstermacher, 
Timothy R. Rebbeck, Angela DeMichele, Barbara 
Weber, DuPont Guerry and Elizabeth Poppert.
Fox Chase Cancer Center
Kate Haney, Steve Brusstar, John Malick, Kate 
Haney, Arlene Capriotti, Andrew Balshem, Robert 
G. Uzzo, Lori J. Goldstein, Stuart R. Lessin, Pat 
Harsche and W.Thomas London.
Kimmel Cancer Center of Thomas Jefferson 
University
Richard L. Davidson, Monica deBaca, Alejandra 
Ruiz Orrico, Adler Hannes, Juan P. Palazzo, Adam 
Dicker, Michael Mastrangelo and Katherine 
Chou.
Pennsylvania State Cancer Institute 
at Milton S. Hershey Medical
Thomas Loughran, Pam Whayland, Pat Swetland, 
Philip Lazarus, Isom Harriet, Dan Beard, Thomas 
Loughran, Alan J. Snyder, Witold B. Rybka, Daniel 
Lorence, Allan Lipton, Harold A. Harvey, Gavin 
Robertson, David Claxton and Richard Rauscher.
The Wistar Institute 
Jenine Carlisle, Russel E. Kaufman, Donald Ewert, 
Elizabeth O’Brien and Meryle Melnicoff.
Drexel University College of Medicine 
Kenneth Blank, Tesfu Hailu, and Sokol Petushi. 
Geisinger Health System
Glenn D. Steele, Jr., Sandy Buckley and Nicole 
Hunter. 
Windber Research Institute
Kim Yantus, Hai Hu, Chris Sheridan, Holly Rigby 
and F. Nicholas Jacobs273
Multi-Institute Approach to Translational Cancer Research
Cancer Informatics 2007:3 
Pittsburgh Life Sciences Greenhouse
Pat Bronder, David Palmer and John H. Glick.
References
[1]  Becich MJ: 2000. The role of the pathologist as tissue reﬁ  ner and 
data miner: the impact of functional genomics on the modern pathol-
ogy laboratory and the critical roles of pathology informatics and 
bioinformatics. Mol. Diagn., 5(4):287–299.
[2]  Eiseman, E., Rand Corporation.: Case studies of existing human 
tissue repositories: “best practices” for a biospecimen resource for 
the genomic and proteomic era (http://www.rand.org/publications/
MG/MG120/). Santa Monica, CA: RAND; 2003.
[3]  Patel, A.A., Gilbertson, J.R., Parwani, A.V., Dhir, R., Datta, M.W., 
Gupta, R., Berman, J.J., Melamed, J., Kajdacsy-Balla, A., Orenstein 
J. et al: 2006. An informatics model for tissue banks - Lessons learned 
from the Cooperative Prostate Cancer Tissue Resource. B.M.C. 
Cancer, 6(1):120.
[4]  Gilbertson, J.R., Gupta, R., Nie, Y., Patel, A.A., Becich, M.J.: 2004.
Automated clinical annotation of tissue bank specimens. Medinfo 
11(Pt 1):607–610.
[5]  Master Settlement Agreement [http://www.attorneygeneral.gov/
uploadedFiles/Consumers/msa.pdf]
[6]  Pennsylvania’s Act 77 of 2001, the Tobacco Settlement Act [http://
www.legis.state.pa.us/WU01/LI/BI/BT/2001/0/HB0002P2378.
HTM]
[7]  Pennsylvania’s Health Research and CURE program [http://www.
dsf.health.state.pa.us/health/cwp/browse.asp?A=175&BMDRN=
2000&BCOB=0&C=38811]
[8] Technology Transfer: Administration of the Bayh-Dole Act by Research 
Universities [http://www.gao.gov/archive/1998/rc98126.pdf]
[9]  Patel, A.A., Kajdacsy-Balla, A., Berman, J.J., Bosland, M., Datta, 
M.W., Dhir, R., Gilbertson, J., Melamed, J., Orenstein, J., Tai, K.F. 
et al. 2005. The development of common data elements for a multi-
institute prostate cancer tissue bank: the Cooperative Prostate Cancer 
Tissue Resource (CPCTR) experience. B.M.C. Cancer, 5:108.
[10]  Melamed, J., Datta, M.W., Becich, M.J., Orenstein, J.M., Dhir, R., 
Silver, S., Fidelia-Lambert, M., Kadjacsy-Balla, A., Macias, V., Patel, 
A. et al: 2004. The cooperative prostate cancer tissue resource: a 
specimen and data resource for cancer researchers. Clin. Cancer, 
Res., 10(14):4614–4621.
[11]  Greene, F.L., American Joint Committee on Cancer., American 
Cancer Society.: AJCC cancer staging manual, 6th edn. New York: 
Springer-Verlag; 2002.
[12]  NAACCR Data Standards for Cancer Registries [http://www.naaccr.
org/index.asp?Col_SectionKey=7&Col_ContentID=122
[13]  The CAP Cancer protocols: Checklist for prostate gland [http://www.
cap.org/apps/docs/cancer_protocols/prostate04_pw.pdf
[14]  The NCICB’s Cancer Data Standards Repository (caDSR) [http://
ncicb.nci.nih.gov/NCICB/infrastructure/cacore_overview/cadsr]
[15]  Winget, M.D., Baron, J.A., Spitz, M.R., Brenner, D.E., Warzel, D., 
Kincaid, H., Thornquist, M., Feng, Z. 2003. Development of common 
data elements: the experience of and recommendations from the early 
detection research network. Int. J. Med. Inform., 70(1):41–48.
[16]  Department of Health and Human Services. 45 CFR (Code of Fed-
eral Regulations), 164.514(6)(2)(i). Standards for Privacy of Indi-
vidually Identiﬁ  able Health Information (ﬁ  nal) [http://www.hhs.
gov/ocr/regtext.html]
[17]  Health Insurance Portability and Accountability Act of 1996 [http://
aspe.hhs.gov/admnsimp/pl104191.htm]
[18]  Dhir, R., Patel, A.A., Winters, S., Grzybicki, D., Bisceglia, M., Swan-
son, D., Aamodt, R., Becich, M.J. 2006. A multi-disciplinary approach 
to honest broker services for tissue banks and clinical data: a prag-
matic and practical model. (In submission). CLin. Canc. Research.
[19]  Solbrig, H.R. 2000. Metadata and the reintegration of clinical infor-
mation: ISO 11179. MD., Comput, 17(3):25–28.
[20]  The ISO/IEC 11179 speciﬁ  cation developed by the National Institute 
of Standards and Technology (NIST) [http://isotc.iso.ch/livelink/
livelink/fetch/2000/2489/Ittf_Home/PubliclyAvailableStandards.
htm]
[21] The  NCI’s Cancer Biomedical Informatics Grid (caBIG) [http://
cabig.nci.nih.gov/]
[22] NCI  Thesaurus [http://nciterms.nci.nih.gov/NCIBrowser/Dictionary.
do]
[23]  Berman, J.J., Datta, M., Kajdacsy-Balla, A., Melamed, J., Orenstein, J., 
Dobbin, K., Patel, A., Dhir, R. and Becich, M.J. 2004. The tissue micro-
array data exchange speciﬁ  cation: implementation by the Cooperative 
Prostate Cancer Tissue Resource. BMC Bioinformatics, 5(1):19.
[24]  Li, S., Becich, M. and Gilbertson, J. 2004. Microarray Data Mining 
Using Gene Ontology. Medinfo.778–782.
[25]  Yu, Y.P., Landsittel, D., Jing, L., Nelson, J., Ren, B., Liu, L., McDonald, 
C., Thomas, R., Dhir, R., Finkelstein, S. et al. 2004. Gene Expression 
Alterations in Prostate Cancer Predicting Tumor Aggression and Preced-
ing Development of Malignancy. J. Clin. Oncol., 22(14): 2790–2799.
[26] Patel, A.A., Gupta, D., Seligson, D., Hattab, E.M., Balis, U.J., 
Ulbright, T.M., Kohane, I.S., Berman, J.J., Gilbertson, J.R., Dry S. 
et al. 2007. Availability and quality of parafﬁ  n blocks identiﬁ  ed in 
pathology archives: a multi-institutional study by the Shared Pathol-
ogy Informatics Network (SPIN). B.M.C., Cancer, 7:37.
[27]  The U.K. Biobank Project [http://www.biobank.ac.uk]
[28]  Swedish National Biobank Program [www.biobanks.se]
[29] ATIP03.042. 2003. The Biobank Japan Project (http://www.atip.
org/public/atip.reports.03/atip03.042.pdf). In: Asian Technology 
Information Program,.
[30]  McCaffrey P. 2003. Iceland’s database tussle http://www.bio-itworld.
com/news/040103_report2255.html. Bio-IT World.
[31]  Australasian Biospecimen Network (ABN) [http://www.abrn.net/]
[32]  Thorn, H.C.D., Devereux, L., MacCallum, P. and Zeps N: 2005. A 
more auspicious start for the Australasian Biospecimen Network 
[Letter to the Editor]. J. Clin. Invest.
[33] The  Singapore  Tissue  Network [http://www.stn.org]
[34] Spinney,  L. 2003. U.K. launches tumor bank to match maligned 
Biobank. Nat. Med., 9(5):491.
[35]  The National Biospecimen Network (NBN) blueprint 
[http://biospecimens.cancer.gov/nbn/blueprint.asp]
[36]  VonEschenbach, A.C., Buetow K. 2006. Cancer Informatics Vision: 
caBIG. Cancer Informatics, 2:22–24.
[37]  Summary of Key Points in the Master Settlement Agreement [http://
www.attorneygeneral.gov/consumers.aspx?id=683]
[38]  CURE Awarded Grants: Health Research Nonformula Grant Awards 
for SFY 2001–02 [http://www.dsf.health.state.pa.us/health/lib/health/
cure/2001_nonformula_grants_sfy_01–02.pdf]
[39] The  Pittsburgh Life Sciences Greenhouse [http://www.pittsburghlife-
sciences.com]
[40]  George J. 2006. Study details tobacco settlement’s boon to Pennsyl-
vania. In: Philadelphia Business Journal.
[41]  National Cancer Advisory Board meeting minutes, November 2004 
[http://deainfo.nci.nih.gov/advisory/ncab/132_1104/30nov04mins.pdf]
[42]  National Cancer Institute’s Board of Scientiﬁ  c Advisors meeting 
minutes, November 2004 [http://deainfo.nci.nih.gov/advisory/bsa/
bsa1104/08nov04mins.htm]
[43]  Cooperative Prostate Cancer Tissue Resource
[http://www.prostatetissues.org]
[44]  The Cooperative Breast Cancer Tissue Resource 
[http://www-cbctr.ims.nci.nih.gov/]
[45]  Cooperative prostate cancer tissue resource: Release Date April 
29,1999, RFA CA-99–012, National Cancer Institute [http://grants1.
nih.gov/grants/guide/rfa-ﬁ  les/RFA-CA-99–012.html]
[46]  Cooperative human tissue network: Release Date March 12, 2000. 
RFA CA-01-009, National Cancer Institute [http://grants.nih.gov/
grants/guide/rfa-ﬁ  les/RFA-CA-01–009.html]
[47]  Cooperative breast cancer tissue registry: Release Date February 
19,1993, RFA CA-93-19, National Cancer Institute [http://grants2.
nih.gov/grants/guide/rfa-ﬁ  les/RFA-CA-93–019.html]274
Patel et al
Cancer Informatics 2007:3 
Supplemental Files
•  The Master List of purposed Biomarkers 
(additional ﬁ  le #1)
•  The Intellectual Property /Technology Trans-
fer Agreements (additional ﬁ  le #2)
•  Biomarker Disclosure Form (additional 
ﬁ  le #3)
•  Template IRB Protocol for PCABC project 
(additional ﬁ  le #4)
•  Template IRB Protocol for the Honest Broker 
system (additional ﬁ  le #5)
•  Universal Consent Template (additional 
ﬁ  le #6)
•  Material Transfer Agreement Template 
(additional ﬁ  le #7)
•  The freely available CDEs developed for breast, 
prostate, and melanoma by the Consortium can 
be downloaded from its public database link on 
the PCABC website. 
 o Prostate CDEs (additional ﬁ  les #8)
 o Breast CDEs (additional ﬁ  les #9)
 o Melanoma CDEs (additional ﬁ  les #10)